Joseph Johnson
Endocrinology, Diabetes & Metabolism · Atlanta, GANPI 1013137934
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 454 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 43 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,533 and has fallen 59.6% since, to $1,022 in 2025.
Across 454 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Abbott$949
- Xeris Pharmaceuticals, Inc.$638
- Novartis$608
- Corcept Therapeutics$563
- Amgen$475
- plus $4K from 37 others
What the payments were for
- Food & beverage$8,626100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$186
- UNITY DIABETES MANAGEMENT SYSTEM$152
- KXL System$129
- RECORLEV$127
- Korlym$110
- AFREZZA$108
- Omnipod$104
How this compares
$8,627 in reported general payments places this provider in the 75th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 24 | $988,990 |
| OzempicSemaglutide | 216 | $407,433 |
| JardianceEmpagliflozin | 105 | $133,170 |
| MounjaroTirzepatide | 57 | $93,069 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 60 | $72,150 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 38 | $64,412 |
| TrulicityDulaglutide | 35 | $56,270 |
| JanuviaSitagliptin Phosphate | 34 | $52,920 |
| FarxigaDapagliflozin Propanediol | 31 | $49,222 |
| JanumetSitagliptin Phos/Metformin Hcl | 30 | $44,967 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $43,217 |
| NovologInsulin Aspart | 88 | $34,046 |
| Tresiba Flextouch U-200Insulin Degludec | 17 | $26,208 |
| HumalogInsulin Lispro | 78 | $26,108 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $25,496 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $563 | $988,99024 claims |
| Novo NordiskOzempic, Novolog, Fiasp, Rybelsus | $1,047 | $481,817330 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $220 | $177,136187 claims |
| Boehringer IngelheimJardiance | $369 | $133,170105 claims |
| MerckJanuvia, Janumet | $54 | $97,88764 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $330 | $74,36871 claims |
| AstraZenecaFarxiga | $316 | $49,22231 claims |
| AbbVieSynthroid | $179 | $2,26223 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $53 | $1,974203 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Atlanta
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Jonathan OwnbyAtlanta$291K
- Gulliermo UmpierrezAtlanta$63K
- Francisco PasquelAtlanta$40K
- Norman WelchAtlanta$25K
- Rachel DerrAtlanta$18K
- Kate WheelerAtlanta$17K
- John ZoraAtlanta$16K
- Ernest BeasleyAtlanta$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.